City

Clinical trials near Melbourne, Australia

Active studies with a listed research site in Melbourne, Australia.

22active studies

18recruiting now

20countries represented

633largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 2

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Obesity, OverweightCondition

Macupatide, EloralintideTreatment

Argentina, Australia42 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07215559See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Obesity With Diabetes, Overweight With DiabetesCondition

Ribupatide, PlaceboTreatment

Argentina, Australia167 locations

KaileraSponsor

Updated 2026-09-03 · NCT07284901See eligibility →

Recruiting nowPhase 3

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

Type 2 DiabetesCondition

Placebo, SurvodutideTreatment

Australia, Canada121 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07754461See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Obesity, OverweightCondition

Ribupatide, PlaceboTreatment

Argentina, Australia104 locations

KaileraSponsor

Updated 2026-09-03 · NCT07284875See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Obesity, OverweightCondition

Eloralintide, PlaceboTreatment

Argentina, Australia162 locations

Eli Lilly and CompanySponsor

Updated 2026-08-21 · NCT07321886See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

Obesity or OverweightCondition

Placebo, EnicepatideTreatment

Argentina, Australia195 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351045See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity or Overweight, Type 2 Diabetes MellitusCondition

Placebo, EnicepatideTreatment

Argentina, Australia193 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351058See eligibility →

Recruiting nowPhase 1

A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight

Obesity, OverweightCondition

VRB-103, PlaceboTreatment

Australia1 locations

Verdiva Bio Dev LimitedSponsor

Updated 2026-08-11 · NCT07628127See eligibility →

Recruiting nowPhase 2

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

UBT251, UBT251 PlaceboTreatment

Australia, Germany70 locations

Novo Nordisk A/SSponsor

Updated 2026-08-10 · NCT07668388See eligibility →

Recruiting nowPhase 1

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZT003 Injection Following Single and Multiple Subcutaneous Administration in Healthy Volunteers/Overweight or Obese Volunteers

HealthyCondition

ZT003 - Part1 (Single ascending dose ), ZT003 - Part 2(Multiple ascending dose )Treatment

Australia2 locations

Beijing QL Biopharmaceutical Co.,LtdSponsor

Updated 2026-07-27 · NCT07184502See eligibility →

Recruiting nowPhase 3

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

Type 2 Diabetes MellitusCondition

Elecoglipron, SemaglutideTreatment

Argentina, Australia201 locations

AstraZenecaSponsor

Updated 2026-07-14 · NCT07662213See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection FractionCondition

Maridebart cafraglutide, PlaceboTreatment

Argentina, Australia628 locations

AmgenSponsor

Updated 2026-07-02 · NCT07037459See eligibility →

Recruiting nowPhase 1

A Phase 1, Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISM8969

Healthy Subjects (HS), Obese Adult Participants at Risk of Cardiovascular DiseaseCondition

ISM8969 tablets or placebo, ISM8969 tablets or placeboTreatment

Australia1 locations

InSilico Medicine Hong Kong LimitedSponsor

Updated 2026-06-22 · NCT07581431See eligibility →

Recruiting nowPhase 1

An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.

ObesityCondition

RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity, PG-102Treatment

Australia1 locations

RANI TherapeuticsSponsor

Updated 2026-04-14 · NCT06891287See eligibility →

Recruiting nowPhase 1, Phase 2

Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity

Obesity &Amp; OverweightCondition

RN3161, Placebo ControlTreatment

Australia1 locations

Ikaria Bioscience Pty LtdSponsor

Updated 2025-11-24 · NCT07245771See eligibility →

Recruiting nowPhase 4

Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)

Obesity, Knee OsteoarthritisCondition

Tirzepatide, PlaceboTreatment

Australia4 locations

University of MelbourneSponsor

Updated 2025-04-30 · NCT06191848See eligibility →

Recruiting nowPhase 1

A Study to Evaluate MWN109 Injection in Healthy Subjects

Overweight or ObeseCondition

Placebo, Subcutaneous single and mutiple doseTreatment

Australia1 locations

Shanghai Minwei Biotechnology Co., LtdSponsor

Updated 2025-04-15 · NCT06859853See eligibility →

Recruiting nowNot applicable

The Bariatric Surgery Registry

ObesityCondition

Intervention not listedTreatment

Australia1 locations

Monash UniversitySponsor

Updated 2024-12-12 · NCT03441451See eligibility →

Opening soonPhase 1

A Study of SYH2092 Injection in Healthy Participants

Overweight or ObesityCondition

SYH2092 Injection, PlaceboTreatment

Australia1 locations

CSPC Megalith Biopharmaceutical Co.,Ltd.Sponsor

Updated 2026-08-20 · NCT07776041See eligibility →

Opening soonPhase 1

A Phase 1, Double-blind, Randomized Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Single Dose and Multiple Doses of CG-0416 in Healthy Participants.

Overweight and ObesityCondition

CG-0416Treatment

Australia1 locations

HongKong Curegene Innovation Co., LimitedSponsor

Updated 2026-07-24 · NCT07724431See eligibility →

Opening soonPhase 2

TriGlytza®-01 Versus Metformin in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin Therapy

Type 2 Diabetes (T2DM)Condition

Metformin XR, CelecoxibTreatment

Australia3 locations

Myopharm LimitedSponsor

Updated 2026-07-08 · NCT07139405See eligibility →

Active, not recruitingPhase 3

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

Cardiovascular DiseaseCondition

Cagrilintide, SemaglutideTreatment

Argentina, Australia633 locations

Novo Nordisk A/SSponsor

Updated 2026-08-31 · NCT05669755See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Melbourne, Australia

Current studies

Related cities